Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $0.42.

  • Teva Pharmaceutical Industries' EPS (Basic) rose 32105.26% to $0.42 in Q4 2025 from the same period last year, while for Dec 2025 it was $1.24, marking a year-over-year increase of 18551.72%. This contributed to the annual value of $1.23 for FY2025, which is 18482.76% up from last year.
  • As of Q4 2025, Teva Pharmaceutical Industries' EPS (Basic) stood at $0.42, which was up 32105.26% from $0.38 recorded in Q3 2025.
  • Teva Pharmaceutical Industries' EPS (Basic)'s 5-year high stood at $0.42 during Q4 2025, with a 5-year trough of -$1.92 in Q4 2022.
  • In the last 5 years, Teva Pharmaceutical Industries' EPS (Basic) had a median value of -$0.04 in 2024 and averaged -$0.21.
  • Its EPS (Basic) has fluctuated over the past 5 years, first crashed by 132857.14% in 2022, then soared by 32105.26% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' EPS (Basic) (Quarter) stood at -$1.01 in 2021, then tumbled by 89.14% to -$1.92 in 2022, then skyrocketed by 121.39% to $0.41 in 2023, then crashed by 146.34% to -$0.19 in 2024, then skyrocketed by 321.05% to $0.42 in 2025.
  • Its last three reported values are $0.42 in Q4 2025, $0.38 for Q3 2025, and $0.25 during Q2 2025.